A new global player in medical technology, TSC Life, has been launched, following the merger of The Surgical Company’s business units specialising in patient temperature management (PTM) and single-use endoscopy. TSC Life will operate as an independent MedTech company, dedicated to advancing innovations in operating room (OR), intensive care unit (ICU), and urology technologies.
The creation of TSC Life marks a significant reorganisation, aiming to streamline operations and drive further growth in key markets. The new firm brings together industry-leading brands such as Mistral Air™, which holds a strong global presence as the second-largest forced air warming provider, and Fluido™, which specialises in blood and fluid warming solutions. TSC Life’s endoscopy division also boasts the Broncoflex™, a fast-growing single-use endoscope, which has emerged as a key challenger in its sector.
Luc Van Schil, Chairman of TSC Life, expressed his enthusiasm for the company’s future: “Our vision is to become the global number one challenger in our space, while remaining independent. We have accelerated investments in product development and manufacturing to meet clinical and economic needs. This will allow us to expand our portfolio and continue delivering cutting-edge healthcare solutions to our customers.”
The merger is expected to help the company leverage the combined expertise of its business units, providing a platform for ambitious growth through product innovation and mergers and acquisitions. The company’s leaders are confident that the synergies created by this integration will help TSC Life build a robust portfolio that caters to the diverse needs of healthcare providers across the world.
Paraic Curtis, CEO of TSC Life, highlighted the company’s strategic approach: “TSC Life is poised for exceptional growth, thanks to our focus on creating solutions that meet the specific needs of healthcare professionals. We have direct sales in key markets, giving us critical insights into industry trends, and our independence allows us to invest in innovation that truly addresses the challenges of the medical sector. With our talented team, we’re ready to deliver better clinical outcomes cost-effectively.”
TSC Life has operations in the UK, Benelux, France, Germany, and the United States and is actively recruiting talent across various sectors. The company’s growth strategy will focus on both internal product development and strategic acquisitions, further strengthening its position in the global market.
As the healthcare industry continues to evolve, TSC Life’s leadership is optimistic that their approach will help the company become a significant player in the MedTech sector. Their commitment to maintaining independence, combined with their call point-centred commercial strategy, will enable TSC Life to develop innovative solutions that improve patient outcomes.
For more information, visit TSC Life’s website at www.tsc-life.com.
